To gain insights into UTX functions for cancer formation and maintenance, we utilized the KDM6 inhibitor, GSK-J4, and UTX-deficient cells created using the CRISPR-Cas9 editing system in conjunction with complementation with exogenous UTX. The gene discussed is KDM6A; the disease is cancer.